NEWS

Vienna, Austria, 16 December 2024: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in San Francisco, January...

Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good progress; target validation and details of…

This is particularly fitting as today is Glioblastoma Awareness Day, to recognize the impact of this most aggressive form of brain cancer and highlight the need to advance research, raise...

• Preclinical study will be conducted by Dr. David Reardon’s research group • Immune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer Vienna, Austria and Boston,…

Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started; invIOs awarded up to 45% funding of trial…

INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indications Treatment with INV501 significantly inhibits tumor growth, extends survival and increases cure...

APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver treatment in under 24 hours Data...

Vienna, Austria, 14 December 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during...

Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a heavily...

Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2 Investigators recommend further development of inhaled APN01, which…

Vienna, Austria, 18 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401,…

Vienna, Austria, 11 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival...

geared towards enabling innovation and growth invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 26 April 2022. APEIRON...

Vienna, Austria, 03 February 2022: invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming investor conferences, the BIO CEO &...

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 16 December 2021: invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for…

Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables…

Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from…